- Structure Therapeutics is focused on developing **oral small molecules** for obesity and diabetes, anticipating that these will expand the market, particularly through primary care physicians.  **[1888886_tx_382494_0]** **[1888886_tx_382494_4]** 
- The company expects **two data readouts** for its lead oral GLP-1 molecule, aleniglapron, from the Access and Access 2 studies by the end of **2025**.  **[1888886_tx_382494_0]** **[1888886_tx_382494_3]** 
- Structure Therapeutics also plans to advance its **oral amylin small molecule (2671)** into the clinic by the end of **2025**, with potential for both monotherapy and combination use.  **[1888886_tx_382494_0]** **[1888886_tx_382494_7]** 
- The company announced **three new studies** for aleniglapron, including a switch study, a body composition study, and a study for individuals with type 2 diabetes and obesity, to inform its Phase 3 design and broaden its label.  **[1888886_tx_382494_2]** **[1888886_tx_382494_3]** 
- Structure Therapeutics is actively seeking a **strategic partner for commercialization** to help realize the full potential of aleniglapron across various indications beyond chronic weight management.  **[1888886_tx_382494_8]**

Structure Therapeutics (GPCR)